vimarsana.com

Latest Breaking News On - Liang cheng - Page 1 : vimarsana.com

ASCO 2024: Artificial Intelligence and Deep Learning in Prostate Cancer Pathology

Vaxart, Inc (NASDAQ:VXRT) Q1 2024 Earnings Call Transcript

Vaxart, Inc (NASDAQ:VXRT) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

Certain A Shares of Anhui Yuanchen Environmental Protection Science&Technology Co , Ltd are subject to a Lock-Up Agreement Ending on 31-MAR-2024

Certain A Shares of Anhui Yuanchen Environmental Protection Science&Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 31-MAR-2024. These A Shares will be under lockup for 1101 days.

Advances in diagnosis and treatment of bladder cancer

Bladder cancer remains a leading cause of cancer death worldwide and is associated with substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare system. Gross hematuria frequently precedes the diagnosis of bladder cancer. Non-muscle-invasive bladder cancer (NMIBC) is managed initially with transurethral resection of a bladder tumor (TURBT), followed by a risk stratified approach to adjuvant intravesical therapy (IVe), and is associated with an overall survival of 90%. However, cure rates remain lower for muscle invasive bladder cancer (MIBC) owing to a variety of factors. NMIBC and MIBC groupings are heterogeneous and have unique pathological and molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers and luminal and basal molecular subtypes of MIBC with distinct treatment responses. For NMIBC, IVe immunotherapy (primarily BCG) is the gold standard treatment for high grade and high risk NMIBC to reduce or pre

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.